Viking Thera (VKTX)

$38.71 +1.27 (3.39%)
Market Cap 4.35B
Revenue (ttm) 0.00
Net Income (ttm) -359.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,122,500
Avg Vol 2,459,012
Day's Range N/A - N/A
Shares Out 116.11M
Stochastic %K 72%
Beta 0.66
Analysts Strong Sell
Price Target $88.50

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4660
Address:
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States
DG20
DG20 Jul. 7 at 2:36 AM
$VKTX This is peer reviewed 👇👇👇👇
0 · Reply
vu_jade
vu_jade Jul. 7 at 2:14 AM
$VKTX another biotech buyout! VRtX buying CRNX $10 billion is an BAR #SKOL
0 · Reply
MRTunity
MRTunity Jul. 6 at 11:37 PM
$VKTX $AUPH read “it takes two to tango” and INSTANTLY GOT PTSD 😵‍💫 PG really did a number on our psyche - Thank God. He is gone 🙏
1 · Reply
Breton2018
Breton2018 Jul. 6 at 10:41 PM
$VKTX need calls tomorrow
0 · Reply
strangetripitsbeen
strangetripitsbeen Jul. 6 at 9:28 PM
$VKTX crnx just got bought. Started running when we did a few weeks ago. Would be sweet if we’re next. They have an fda approved product but we have better potential. IMO. Own both. Way more vktx
1 · Reply
Elevator_up
Elevator_up Jul. 6 at 9:14 PM
$VKTX • Second row ** we finished green at the bell. 🔔 #Vikingrow • Q3 - countdown to maintenance data ✔️
0 · Reply
dyrn
dyrn Jul. 6 at 9:02 PM
$VKTX diverged from XBI today at end of day, great news after following it for a long time.
1 · Reply
Apopka_FL_Degenerate
Apopka_FL_Degenerate Jul. 6 at 9:00 PM
$VKTX @Johnquest123 not really..... I just like to step on the toes of my dance partners.
1 · Reply
Alligator
Alligator Jul. 6 at 8:51 PM
$VKTX still and always
0 · Reply
DG20
DG20 Jul. 6 at 8:24 PM
$VKTX This holds true and maintenance should be fine. VK2735’s tolerability data is superb…
0 · Reply
Latest News on VKTX
Viking catalysts include VK3019, VK2735 readouts in Q3, says Raymond James

2026-06-24T15:00:11.000Z - 12 days ago

Viking catalysts include VK3019, VK2735 readouts in Q3, says Raymond James

Viking Therapeutics begins Phase 1 SAD clinical trial of VK3019

2026-06-24T11:10:10.000Z - 12 days ago

Viking Therapeutics begins Phase 1 SAD clinical trial of VK3019

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Jun 24, 2026, 7:05 AM EDT - 12 days ago

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Viking Therapeutics management to meet with B. Riley

2026-06-15T16:23:17.000Z - 21 days ago

Viking Therapeutics management to meet with B. Riley

Viking Therapeutics names Hubert Chen, M.D., as Chief Medical Officer

2026-06-11T11:11:15.000Z - 25 days ago

Viking Therapeutics names Hubert Chen, M.D., as Chief Medical Officer

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D.

Jun 11, 2026, 7:05 AM EDT - 25 days ago

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D.

Viking Therapeutics Slides: Corporate presentation

Jun 7, 2026, 7:00 AM EDT - 4 weeks ago

Viking Therapeutics Slides: Corporate presentation

Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 1:25 PM EDT - 4 weeks ago

Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Viking Therapeutics initiated with a Buy at Lake Street

2026-05-28T13:23:51.000Z - 5 weeks ago

Viking Therapeutics initiated with a Buy at Lake Street

Viking Therapeutics assumed with a Buy at Truist

2026-05-27T15:22:10.000Z - 5 weeks ago

Viking Therapeutics assumed with a Buy at Truist

Viking Therapeutics to Participate at Upcoming Investor Conferences

May 21, 2026, 7:05 AM EDT - 6 weeks ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

2026-05-12T12:50:07.000Z - 7 weeks ago

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

May 12, 2026, 7:05 AM EDT - 7 weeks ago

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

ECO

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

May 5, 2026, 7:05 AM EDT - 2 months ago

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

ECO

Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald

2026-04-30T17:16:19.000Z - 2 months ago

Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald

Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley

2026-04-30T14:12:18.000Z - 2 months ago

Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley

Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)

2026-04-29T21:38:53.000Z - 2 months ago

Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)

Viking Therapeutics Earnings Call Transcript: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 2 months ago

Viking Therapeutics Earnings Call Transcript: Q1 2026

Viking Therapeutics Earnings release: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 2 months ago

Viking Therapeutics Earnings release: Q1 2026

Viking Therapeutics Quarterly report: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 2 months ago

Viking Therapeutics Quarterly report: Q1 2026

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Apr 29, 2026, 4:05 PM EDT - 2 months ago

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Apr 22, 2026, 4:35 PM EDT - 2 months ago

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Viking Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 3 months ago

Viking Therapeutics Proxy statement: Proxy filing

Viking Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 3 months ago

Viking Therapeutics Proxy statement: Proxy filing

Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735

2026-03-26T11:11:25.000Z - 3 months ago

Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Mar 26, 2026, 7:05 AM EDT - 3 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 4 months ago

Viking Therapeutics Slides: Corporate presentation

Viking Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:40 AM EDT - 4 months ago

Viking Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Viking Therapeutics management to meet with Truist

2026-03-03T17:37:55.000Z - 4 months ago

Viking Therapeutics management to meet with Truist

Viking Therapeutics rises 10.7%

2026-02-23T17:07:01.000Z - 4 months ago

Viking Therapeutics rises 10.7%

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Feb 11, 2026, 5:10 PM EST - 5 months ago

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Viking Therapeutics Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 5 months ago

Viking Therapeutics Earnings Call Transcript: Q4 2025

Viking Therapeutics Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 5 months ago

Viking Therapeutics Annual report: Q4 2025

Viking Therapeutics Earnings release: Q4 2025

Feb 11, 2026, 4:30 PM EST - 5 months ago

Viking Therapeutics Earnings release: Q4 2025

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Feb 11, 2026, 4:16 PM EST - 5 months ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Feb 4, 2026, 4:05 PM EST - 5 months ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 5 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO PFE

Viking Therapeutics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 6 months ago

Viking Therapeutics Slides: Corporate presentation

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 7:19 PM EST - 6 months ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Viking Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:15 PM EST - 6 months ago

Viking Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 12, 2026, 7:00 AM EST - 6 months ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 8, 2026, 7:00 AM EST - 6 months ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 7, 2026, 7:00 AM EST - 6 months ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:03 PM EST - 6 months ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

Jan 5, 2026, 10:57 AM EST - 6 months ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Viking Therapeutics Slides: Corporate presentation

Dec 9, 2025, 7:00 AM EST - 7 months ago

Viking Therapeutics Slides: Corporate presentation

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 7 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Viking Therapeutics Slides: Corporate Presentation

Nov 19, 2025, 7:00 AM EST - 8 months ago

Viking Therapeutics Slides: Corporate Presentation

Viking Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:00 AM EST - 8 months ago

Viking Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 19, 2025, 2:55 AM EST - 8 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Nov 6, 2025, 7:05 AM EST - 8 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 29, 2025, 4:05 PM EDT - 8 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Viking Therapeutics Earnings Call Transcript: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 9 months ago

Viking Therapeutics Earnings Call Transcript: Q3 2025

Viking Therapeutics Quarterly report: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 9 months ago

Viking Therapeutics Quarterly report: Q3 2025

Viking Therapeutics Earnings release: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 9 months ago

Viking Therapeutics Earnings release: Q3 2025

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 22, 2025, 4:05 PM EDT - 9 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 21, 2025, 7:05 AM EDT - 9 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 15, 2025, 4:05 PM EDT - 9 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Viking Therapeutics Slides: Corporate Presentation

Oct 1, 2025, 7:00 AM EDT - 9 months ago

Viking Therapeutics Slides: Corporate Presentation

Viking Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 23, 2025, 11:20 AM EDT - 10 months ago

Viking Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Viking Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 3:20 PM EDT - 10 months ago

Viking Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 20, 2025, 9:50 AM EDT - 11 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 9:38 PM EDT - 11 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 6:27 PM EDT - 11 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 1:45 PM EDT - 11 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:19 PM EDT - 11 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Aug 19, 2025, 12:05 PM EDT - 11 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Aug 19, 2025, 11:00 AM EDT - 11 months ago

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Aug 19, 2025, 9:39 AM EDT - 11 months ago

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Aug 19, 2025, 9:11 AM EDT - 11 months ago

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Aug 19, 2025, 8:57 AM EDT - 11 months ago

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Viking Therapeutics Transcript: Study Result

Aug 19, 2025, 8:00 AM EDT - 11 months ago

Viking Therapeutics Transcript: Study Result

Viking Therapeutics Press release: Study Result

Aug 19, 2025, 8:00 AM EDT - 11 months ago

Viking Therapeutics Press release: Study Result

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Aug 19, 2025, 7:18 AM EDT - 11 months ago

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Aug 19, 2025, 7:08 AM EDT - 11 months ago

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics Earnings Call Transcript: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q2 2025

Viking Therapeutics Quarterly report: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Quarterly report: Q2 2025

Viking Therapeutics Earnings release: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings release: Q2 2025

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 23, 2025, 4:05 PM EDT - 1 year ago

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Jul 16, 2025, 4:05 PM EDT - 1 year ago

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Viking Therapeutics Slides: Corporate Presentation

Jul 3, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

Jun 25, 2025, 7:03 AM EDT - 1 year ago

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 1 year ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN GPCR LLY NVO PFE REGN XBI

Viking Therapeutics Slides: Corporate Presentation

Jun 14, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Viking Therapeutics Slides: Company Presentation

May 2, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Company Presentation

Viking Therapeutics Earnings Call Transcript: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q1 2025

Viking Therapeutics Quarterly report: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Quarterly report: Q1 2025

Viking Therapeutics Earnings release: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings release: Q1 2025

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Viking Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Will Pfizer approach Viking Therapeutics with a buyout proposal?

Apr 15, 2025, 3:26 PM EDT - 1 year ago

Will Pfizer approach Viking Therapeutics with a buyout proposal?

Viking Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Viking Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Mar 26, 2025, 7:05 AM EDT - 1 year ago

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.

Mar 12, 2025, 11:54 AM EDT - 1 year ago

Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.

Viking Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 9:20 AM EDT - 1 year ago

Viking Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

Mar 11, 2025, 7:03 AM EDT - 1 year ago

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

Viking Therapeutics Slides: Corporate Presentation

Feb 6, 2025, 7:00 AM EST - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

Viking Therapeutics Earnings Call Transcript: Q4 2024

Feb 5, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q4 2024

Viking Therapeutics Annual report: Q4 2024

Feb 5, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Annual report: Q4 2024

Viking Therapeutics Earnings release: Q4 2024

Feb 5, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Earnings release: Q4 2024

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Feb 5, 2025, 4:05 PM EST - 1 year ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

Jan 29, 2025, 4:05 PM EST - 1 year ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

Why this Weight-Loss Drug Stock Could Gain 200%

Jan 23, 2025, 7:38 AM EST - 1 year ago

Why this Weight-Loss Drug Stock Could Gain 200%

Viking Therapeutics Slides: Corporate Presentation

Jan 23, 2025, 7:00 AM EST - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

What's next for Viking Therapeutics? Here's how the company can scale up.

Jan 21, 2025, 3:04 PM EST - 1 year ago

What's next for Viking Therapeutics? Here's how the company can scale up.

DG20
DG20 Jul. 7 at 2:36 AM
$VKTX This is peer reviewed 👇👇👇👇
0 · Reply
vu_jade
vu_jade Jul. 7 at 2:14 AM
$VKTX another biotech buyout! VRtX buying CRNX $10 billion is an BAR #SKOL
0 · Reply
MRTunity
MRTunity Jul. 6 at 11:37 PM
$VKTX $AUPH read “it takes two to tango” and INSTANTLY GOT PTSD 😵‍💫 PG really did a number on our psyche - Thank God. He is gone 🙏
1 · Reply
Breton2018
Breton2018 Jul. 6 at 10:41 PM
$VKTX need calls tomorrow
0 · Reply
strangetripitsbeen
strangetripitsbeen Jul. 6 at 9:28 PM
$VKTX crnx just got bought. Started running when we did a few weeks ago. Would be sweet if we’re next. They have an fda approved product but we have better potential. IMO. Own both. Way more vktx
1 · Reply
Elevator_up
Elevator_up Jul. 6 at 9:14 PM
$VKTX • Second row ** we finished green at the bell. 🔔 #Vikingrow • Q3 - countdown to maintenance data ✔️
0 · Reply
dyrn
dyrn Jul. 6 at 9:02 PM
$VKTX diverged from XBI today at end of day, great news after following it for a long time.
1 · Reply
Apopka_FL_Degenerate
Apopka_FL_Degenerate Jul. 6 at 9:00 PM
$VKTX @Johnquest123 not really..... I just like to step on the toes of my dance partners.
1 · Reply
Alligator
Alligator Jul. 6 at 8:51 PM
$VKTX still and always
0 · Reply
DG20
DG20 Jul. 6 at 8:24 PM
$VKTX This holds true and maintenance should be fine. VK2735’s tolerability data is superb…
0 · Reply
saifnila2
saifnila2 Jul. 6 at 8:05 PM
$VKTX volume spike at close. Almost 500 k in the last few minutes. Excellent finish.
0 · Reply
SlimyMango
SlimyMango Jul. 6 at 8:04 PM
$VKTX respectable close
0 · Reply
RunGal
RunGal Jul. 6 at 8:01 PM
$VKTX Excellent close.
0 · Reply
Randini
Randini Jul. 6 at 8:01 PM
$VKTX up from 38.08 @3:45 .... Nice close!!!!!
0 · Reply
Apopka_FL_Degenerate
Apopka_FL_Degenerate Jul. 6 at 8:01 PM
$VKTX @randies @Kylenorth @Johnquest123
1 · Reply
CalledThis1
CalledThis1 Jul. 6 at 8:00 PM
$VKTX wow that post went sour for you real quick. My screen shows up over 3%
0 · Reply
Apopka_FL_Degenerate
Apopka_FL_Degenerate Jul. 6 at 7:58 PM
$VKTX i see it going back up.
0 · Reply
jmartin795
jmartin795 Jul. 6 at 7:58 PM
$VKTX nice pick up
0 · Reply
saifnila2
saifnila2 Jul. 6 at 7:51 PM
$VKTX low volume always means that she goes down like clockwork. The only way this goes up with conviction is high volume. Its the olgas playing games but very predictable.
1 · Reply
randies
randies Jul. 6 at 7:49 PM
$VKTX hahahahaha straight line down 😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂
2 · Reply
Kylenorth
Kylenorth Jul. 6 at 7:45 PM
$VKTX red finish. thanks for the free 36 puts
2 · Reply
Stockman824
Stockman824 Jul. 6 at 7:12 PM
$VKTX can you imagine if we could get to the point where we are in a real competition for dominance in the WL field. Getting 25-30% share?!?!?!? Let’s not forget that Lipitor (now generic Atotvastatin) was not first to market but BIC and took over market share. WELL we will be BIFC!!!!!!!
0 · Reply